Seelos Therapeutics to Webcast Presentation at the 39th Annual Cowen Health Care Conference and Participate in the 31st Annual ROTH Conference
06 mars 2019 08h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, March 06, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, announced today that they will webcast their presentation at the...
Seelos Therapeutics to Present at the 39th Annual Cowen Health Care Conference
01 mars 2019 09h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, March 01, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that they will participate in the 39th Annual Cowen...
Seelos Therapeutics Completes Acquisition of Trehalose from Bioblast Pharma
19 févr. 2019 08h00 HE
|
Seelos Therapeutics, Inc.
Diversifies Seelos’ pipeline in rare diseases Collaborates with Team Sanfilippo Foundation in development of Trehalose in Sanfilippo syndrome NEW YORK, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Seelos...
Seelos Therapeutics, Inc. Announces Successful Completion of its Merger with Apricus Biosciences, Inc. to Advance Late-Stage Pipeline of Products for Central Nervous System (CNS) Disorders
24 janv. 2019 08h01 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to...
Apricus Biosciences Stockholders Approve Proposed Merger with Seelos Therapeutics, Inc.
15 janv. 2019 07h00 HE
|
Apricus Biosciences, Inc.
SAN DIEGO, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq: APRI) has today reported that it obtained stockholder approval as required pursuant to the terms of the merger...
Apricus Biosciences Adjourns Special Meeting of Stockholders to New Date
14 déc. 2018 12h30 HE
|
Apricus Biosciences, Inc.
SAN DIEGO, Dec. 14, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq: APRI) has today convened and adjourned its special meeting of stockholders in order to obtain specific stockholder...
Apricus Biosciences Reminds Shareholders to Vote Before the Special Meeting on December 14, 2018
10 déc. 2018 07h00 HE
|
Apricus Biosciences, Inc.
Seeking Shareholder Approval for Proposed Merger with Seelos Therapeutics, Inc. SAN DIEGO, Dec. 10, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq: APRI), a biopharmaceutical company...
Apricus Biosciences Provides Corporate Update and Third Quarter 2018 Financial Results
31 oct. 2018 16h24 HE
|
Apricus Biosciences, Inc.
Company Merger with Seelos Therapeutics, Inc. Expected to Close in Fourth Quarter 2018 Apricus Shareholders Expected to Own ~15% of Estimated $94 Million Combined Company Valuation at Closing ...
Apricus Biosciences Provides Corporate Update and Second Quarter 2018 Financial Results
09 août 2018 16h05 HE
|
Apricus Biosciences, Inc.
Company Enters Into Merger Agreement with Seelos Therapeutics, Inc. Apricus Shareholders Expected to Own ~14% of Combined Company Based on Estimated $90 Million Valuation at Closing Merger Expected...
Apricus Biosciences, Inc. Announces Merger Agreement with Seelos Therapeutics, Inc. to Advance Late-Stage Pipeline of Products for Central Nervous System (CNS) Disorders
30 juil. 2018 08h00 HE
|
Apricus Biosciences, Inc.
Transaction to result in Nasdaq-listed company focused on developing novel products to treat central nervous system diseasesTransaction expected to advance Seelos’ robust, late-stage pipeline of five...